Ventris Medical has formed to market Cellesta™, a full line of placental allograft products for surgical and non-surgical applications. Products will be available in the U.S. in flowable and sheet formats.
Cellesta amnion products are minimally manipulated, placental-derived, chorion-free and shelf-stable, with application in orthopaedic, general and plastic surgery, wound care and urologic procedures. Cellesta products are processed using Clearant™, Ventris’ proprietary preservation technology, and will be regulated by the FDA Center for Biologics Evaluation and Research.
Ventris is founded by entrepreneur Russell Cook, previous founder of start-ups such as Summit Surgical, Radius Medical (acquired by NuVasive in 2007) and Biostructures (acquired by Bioventus in 2015).
Sources: Ventris Medical, Inc.; ORTHOWORLD Inc.